Skip to Content

T. Rowe Price Health Sciences PRHSX

Analyst rating as of
NAV / 1-Day Return
92.45  /  0.41 %
Total Assets
15.3 Bil
Adj. Expense Ratio
0.760%
Expense Ratio
0.760%
Fee Level
Low
Longest Manager Tenure
4.47 years
Category
US Fund Health
Investment Style
Large Growth
Min. Initial Investment
2,500
Status
Open
TTM Yield
0.05%
Turnover
39%
Premium

Morningstar’s Analysis

Will PRHSX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Upgraded as the team settles in.

Summary

| |

T. Rowe Price Health Sciences' newest team members are settling in nicely, leading to an upgrade in its Morningstar Analyst Rating to Bronze from Neutral.

Unlock our full analysis with Morningstar Premium